Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Piperazine fibrinogen antagonists from Thomae

Aug. 9, 1996

RO-11 demonstrates efficacy in phase III as DVT prevention agent

Aug. 9, 1996

Thrombin inhibitors inhelabo's pipeline

Aug. 9, 1996

RPR's enoxaparin reduces risk of DVT following hip replacement

Aug. 9, 1996

Hemaseel HMN phase I results announced

Aug. 9, 1996

Antithrombotic/antiallergic TxA2 synthase inhibitors from Terumo

July 26, 1996

Pharmacia & Upjohn introduces new dosage strength for Fragmin

July 26, 1996

D-HG: DIC/thrombosis treatment

July 26, 1996

BASF reports thrombin inhibitors

July 26, 1996

The Immune Response Corporation and Bayer to codevelop hemophilia A gene therapy

July 19, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...